Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Multidrug-resistant Tuberculosis (MDR TB) is emerging public health concern globally. Lost to follow-up (LTFU) is one of the key challenge in MDRTB treatment. In 2013, 18% of MDR TB patients were reported LTFU in India. A qualitative study was conducted to obtain better understanding of both patient and provider related factors for LTFU among MDR TB treatment.
Methods: Qualitative semi-structured personal interviews were conducted with 20 MDRTB patients reported as LTFU and 10 treatment providers in seven districts linked to Nagpur Drug resistant TB Centre (DRTBC) during August 2012-February 2013. Interviews were transcribed and inductive content analysis was performed to derive emergent themes.
Results: We found multiple factors influencing MDR TB treatment adherence. Barriers to treatment adherence included drug side effects, a perceived lack of provider support, patient financial constraints, conflicts with the timing of treatment services, alcoholism and social stigma.
Conclusions: Patient adherence to treatment is multi-factorial and involves individual patient factors, provider factors, and community factors. Addressing issue of LTFU during MDRTB treatment requires enhanced efforts towards resolving medical problems like adverse drug effects, developing short duration treatment regimens, reducing pill burden, motivational counselling, flexible timings for DOT services, social, family support for patients & improving awareness about disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547708 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0135802 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Black hairy tongue (BHT), or lingua villosa nigra, is a rare adverse effect of linezolid, an antibiotic frequently used in the treatment of multidrug-resistant tuberculosis (MDR-TB). We present a case of a 24-year-old female who developed BHT while receiving linezolid as part of a longer regimen for MDR-TB. The patient exhibited a typical BHT presentation, with painless brown-to-black discoloration on the posterior dorsal surface of her tongue, appearing 25 days after initiating linezolid therapy.
View Article and Find Full Text PDFDistribution of nontuberculous Mycobacteria among presumptive drug resistance tuberculosis patients from a ministry of health drug resistance surveillance program, in western Kenya.
J Clin Tuberc Other Mycobact Dis
December 2025
Maseno University, School of Public and Community Development, Department of Biomedical Sciences and Technology, Kisumu, Kenya.
Introduction: Nontuberculous Mycobacteria (NTM) species are emerging pathogens causing Pulmonary diseases with no definitive treatment. Molecular techniques enable characterization and drug resistance profiling, this study sought to determine NTM prevalence, circulating species, and distribution factors among presumptive multidrug-resistant tuberculosis (MDR-TB) patients in western Kenya.
Method: Sputum samples were collected between March through October 2022, and transported for testing at Kenya Medical Research Institute (KEMRI) TB laboratory, in Kisumu.
Prevalence and epidemiological pattern of drug-resistant tuberculosis among migrant populations in Wenzhou City, China, 2014-2023: implications for public health strategies.
Front Public Health
September 2025
Department of Clinical Laboratory Medicine, The Ding Li Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou, China.
Objective: This study aimed to analyze the epidemiological characteristics and trends of notified multidrug-resistant tuberculosis (MDR-TB) in Wenzhou City, China, from 2014 to 2023, with a focus on differences between migrant and local populations among reported TB cases.
Methods: This was a facility-based retrospective cohort study that included all bacteriologically confirmed TB cases notified between 1 January 2014 and 31 December 2023 in the Tuberculosis Information Management System (TBIMS) of the Chinese Center for Disease Control and Prevention and the hospital's laboratory information system, provided they had available phenotypic drug-susceptibility testing (pDST) results. Pearson's chi-square test was used to compare drug-resistance rates between groups, the trend chi-square test was applied to assess temporal changes, and a Sankey diagram was employed to illustrate the origins and intra-city distribution of MDR-TB among the migrant population.
Evaluation of cycloserine dose regimens in an Indian cohort with multidrug-resistant tuberculosis: a population pharmacokinetic analysis.
Antimicrob Agents Chemother
September 2025
Research Laboratories, P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India.
Cycloserine is recommended for inclusion in regimens for multidrug-resistant tuberculosis (MDR-TB). Its efficacy is time dependent and relies on the concentration remaining above the minimum inhibitory concentration (MIC); however, there is a concentration-dependent risk of neurotoxicity. Limited pharmacokinetic (PK) data are available in individuals of Indian origin, despite the high burden of MDR-TB in India.
View Article and Find Full Text PDFEmergence of extensively and pan-drug resistance in clinical bacterial isolates: A systematic scoping review from Ethiopian public health perspective.
PLoS Negl Trop Dis
August 2025
Department of Medical and Surgical Nursing, Faculty of Nursing, University of Tabuk, Tabuk, Saudi Arabia.
Introduction: The growing challenge of antimicrobial resistance in Ethiopia and itsprogression towards XDR and PDR has become a critical public health concern. Therefore, thisreview determined the current state of emerging XDR and PDR bacteria, including pre-XDR and XDR-TB, their contributing factors, advancements, and future perspectives against drug-resistant bacteria, as well as their implications for public health and insights for future research.
Methodology: This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines.